Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Receivables (2016 - 2024)

Spyre Therapeutics (SYRE) has disclosed Receivables for 5 consecutive years, with $5.9 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Receivables changed N/A year-over-year to $5.9 million, compared with a TTM value of $5.9 million through Dec 2024, changed N/A, and an annual FY2024 reading of $5.9 million, changed N/A over the prior year.
  • Receivables was $5.9 million for Q4 2024 at Spyre Therapeutics, roughly flat from $5.9 million in the prior quarter.
  • Across five years, Receivables topped out at $21.5 million in Q1 2021 and bottomed at $5.9 million in Q2 2024.